JPRN-UMIN000050778RecruitingUnknown
JAPANESE PROSPECTIVE REAL WORLD REGISTRY OF CABOZANTINIB PLUS NIVOLUMABIN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC RENAL CELL CARCINOMA - JACUMET study
Kindai University School of Medicine0 sites200 target enrollmentStarted: April 6, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Unknown
- Status
- Recruiting
- Sponsor
- Enrollment
- 200
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1)Synchronous or metachronous (within 3 years) malignancies. 2)Surgery prior to initiation of cabozantinib + nivolumab combination therapy with incomplete wound healing or continued postoperative complications 3) Radiotherapy within 14 days before starting cabozantinib + nivolumab combination therapy. Must be fully recovered from radiotherapy
Investigators
Similar Trials
Recruiting
Unknown
JAPANESE PROSPECTIVE REAL WORLD REGISTRY OF CABOZANTINIB PLUS NIVOLUMABIN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC RENAL CELL CARCINOMAadvanced or metastatic renal cell carcinomaJPRN-UMIN000052855Kinki University50
Completed
Not Applicable
JAPANESE PROSPECTIVE REAL WORLD REGISTRY OF NIVOLUMAB PLUS IPILIMUMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED, ADVANCED OR METASTATIC RENAL CELL CARCINOMA (ARCC) CATEGORIZED INTO IMDC INTERMEDIATE/POOR RISKS (J-ENCORE)ADVANCED OR METASTATIC RENAL CELL CARCINOMAJPRN-UMIN000036772Bristol-Myers Squibb K.K. Ono Pharmaceutical CO.,LTD.286
Not yet recruiting
Unknown
Japanese National RegistryPKD(JRP)autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney diseaseJPRN-jRCT1030230618Muto Satoru1,100
Recruiting
Not Applicable
Establishment of Japanese-originated comprehensive biomarker system for diagnosis and stratification of patients with various types of dementias based on multicenter alliance for brain biomarkers (MABB)Mild cognitive impairmentJPRN-UMIN000047214Japan Agency for Medical Research and Development240
Recruiting
Not Applicable
J-REGISTER: Japanese REal-world data for treatment of afatinib (GIotrif) in first-line setting and Subsequent Therapies for patients with advanced EGFR mutation-positive lung adenocarcinomaJPRN-UMIN000044071ippon Boehringer Ingelheim Co., Ltd.1,000